TY - JOUR
T1 - Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis
T2 - A single-blind case-control study
AU - Habib, George
AU - Khazin, Fadi
AU - Jabbour, Adel
AU - Chernin, Mark
AU - Badarny, Samih
AU - Hakim, Jeries
AU - Artul, Suheil
PY - 2014/3
Y1 - 2014/3
N2 - Objective: The objective of this study was to evaluate the effect of simultaneous bilateral intra-articular injection (IAI) of methylpredniso-lone acetate (MPA) on the hypothalamic-pituitary-adrenal axis in patients with knee osteoarthritis. Methods: Nonselected patients with symptomatic bilateral knee oste-oarthritis had simultaneous IAI of 80 mg MPA at each knee (group 1). Just before the injection and on weeks 1, 2, 4, 6, and 8 after it, patients had 1 μg adrenocorticotropin hormone stimulation test. Age- and sex-matched patients had simultaneous IAI of 60 mg of hyaluronic acid in each knee (group 2) and the same protocol of adrenocorticotropin hormone stimulation tests. Demographic, clinical, and laboratory parameters were documentedin all the patients. Secondary adrenal insufficiency (SAI) was defined as poststimulation serum cortisol levels of less than 18 μg/dL. Results: Twenty patients were enrolled in each group. There were 15 women and 5 men in each group. Mean age of the patients in group 1 was 60.3 (SD, 7.6) years. Twelve patients (60%) from group 1 had evidence of SAI versus 3 patients in group 2 (P = 0.003). In all the patients who had SAI in group 1, it was observed in week 1 with decreasing frequency of SAI at the subsequent time points. Yet, 2 patients (10%) from group 1 had evidence of SAI 8 weeks after the IAI. Secondary adrenal insufficiency did not significantly correlate with any demographic, clinical, or laboratory parameter. Conclusions: Secondary adrenal insufficiency was very common following simultaneous bilateral IAI of 80 mg of MPA. Although it was transient, SAI could still be observed nearly 2 months after the IAI, in 10% of the patients.
AB - Objective: The objective of this study was to evaluate the effect of simultaneous bilateral intra-articular injection (IAI) of methylpredniso-lone acetate (MPA) on the hypothalamic-pituitary-adrenal axis in patients with knee osteoarthritis. Methods: Nonselected patients with symptomatic bilateral knee oste-oarthritis had simultaneous IAI of 80 mg MPA at each knee (group 1). Just before the injection and on weeks 1, 2, 4, 6, and 8 after it, patients had 1 μg adrenocorticotropin hormone stimulation test. Age- and sex-matched patients had simultaneous IAI of 60 mg of hyaluronic acid in each knee (group 2) and the same protocol of adrenocorticotropin hormone stimulation tests. Demographic, clinical, and laboratory parameters were documentedin all the patients. Secondary adrenal insufficiency (SAI) was defined as poststimulation serum cortisol levels of less than 18 μg/dL. Results: Twenty patients were enrolled in each group. There were 15 women and 5 men in each group. Mean age of the patients in group 1 was 60.3 (SD, 7.6) years. Twelve patients (60%) from group 1 had evidence of SAI versus 3 patients in group 2 (P = 0.003). In all the patients who had SAI in group 1, it was observed in week 1 with decreasing frequency of SAI at the subsequent time points. Yet, 2 patients (10%) from group 1 had evidence of SAI 8 weeks after the IAI. Secondary adrenal insufficiency did not significantly correlate with any demographic, clinical, or laboratory parameter. Conclusions: Secondary adrenal insufficiency was very common following simultaneous bilateral IAI of 80 mg of MPA. Although it was transient, SAI could still be observed nearly 2 months after the IAI, in 10% of the patients.
KW - Bilateral intra-articular injection
KW - Knee joint
KW - Methylprednisolone acetate
KW - Secondary adrenal insufficiency
UR - https://www.scopus.com/pages/publications/84896777716
U2 - 10.2310/jim.0000000000000048
DO - 10.2310/jim.0000000000000048
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24430212
AN - SCOPUS:84896777716
SN - 1081-5589
VL - 62
SP - 621
EP - 626
JO - Journal of Investigative Medicine
JF - Journal of Investigative Medicine
IS - 3
ER -